- Company
- The market share of GLP-1 diabetes drug Trulicity is 99%
- by An, Kyung-Jin Nov 30, 2020 06:21am
- Trulicity, a diabetic treatment administered once a week, continues to dominate in the GLP-1 analog market. Despite the confusion of COVID-19 outbreak, it has set a new quarterly sales record, reaching &8361;40 billion in annual sales. It is leading the market expansion by recording a market share of over 99% with only a single item. Acco
- Company
- First generic release isn't related to original price cuts
- by Kim, Jin-Gu Nov 30, 2020 06:20am
- The Supreme Court of South Korea finally ruled that the company that launched First Generic due to the success of its patent strategy had no reason to be responsible for lowering the drug price of the original drug. The results of the Zyprexa (Olanzapine) lawsuit came out after 10 years. The result of this lawsuit received great attention
- Company
- Prevenar and Sky Cellflu soar, Keytruda tops again
- by Chon, Seung-Hyun Nov 30, 2020 06:20am
- The novel coronavirus infection (COVID-19) has shuffled the top pharmaceutical market leader board. While immunotherapy Keytruda topped the market again, the sales in a pneumococcal 13-valent conjugate vaccine Prevenar 13 and a flu vaccine Sky Cellflu 4 surged dramatically. The sales in innovative new drugs like Tagrisso and Prolia also grew not
- Product
- High risk in bone fracture found with long-term GCs use
- by Lee, in-bok Nov 30, 2020 06:20am
- A study claims a long-term prescription of glucocorticoid (GCs) could raise the risk of osteoporosis and bone fracture even in South Koreans. The researchers found the bone density dips significantly and the risk goes up high three months into the prescription. So far, there were studies condudcted in the U.S. and Europe warning such risks,
- Policy
- NA urges for more COVID-19 vaccine, MOHW to take a survey
- by Lee, Jeong-Hwan Nov 27, 2020 06:29am
- The National Assembly Health and Welfare Committee pressured the Ministry of Health and Welfare (MOHW) and the Ministry of Food and Drug Safety (MFDS) to focus their capacity to seek access to investigational COVID-19 vaccines around the world. Also they ordered the South Korean government to extinguish the people’s concerns about the
- Product
- The amount of prescriptions for NSAIDS is increasing rapidly
- by Lee, in-bok Nov 27, 2020 06:29am
- The number of prescriptions for non-steroidal anti-inflammatory drugs (NSAIDS), which are contraindicated for hypertension, asthma patients, and pregnant women, was continuously increasing. Celecoxib took up the most prescription ingredients, and Celebrex recorded the most prescriptions. In particular, Daewon's Pelubi drew attention as it was m
- Policy
- A second survey of expenditure reports was initiated
- by Lee, chang-jin Nov 27, 2020 06:26am
- A second survey of expenditure reports was initiated that documented the economic benefits that health authorities legally provided to medical personnel. The related industry is straining as meticulous inspections are expected to be carried out in order to strengthen the management of expenditure reports such as indirect rebates pointed out i
- Policy
- Contracts with modified indications are not terminated
- by Lee, Hye-Kyung Nov 26, 2020 08:58am
- The NHIS said that in the case of drugs that benefit from the RSA drug price negotiations, it cannot unilaterally terminate the existing contract to change the main indication. Based on the provisions of the NHIS on October 8th, the 'Detailed Operation Guidelines for Risk-Sharing Drug Price Negotiations', the contract cannot be terminated if
- Policy
- RSA's collateral period was reduced by 3 months
- by Lee, Hye-Kyung Nov 26, 2020 08:38am
- The amount of collateral that pharmaceutical companies have to pay when signing an RSA drug is expected to decrease by 25%. According to the 'Detailed Operation Guidelines for Drug Price Negotiation of the Risk Sharing Agreement' revised by The NHIS on October 8, the period of collateral has been changed from 12 months to 9 months. This is be
- Company
- Beovu treating AMD passes the first gate to reimbursement
- by Eo, Yun-Ho Nov 26, 2020 06:05am
- A novel neovascular age-related Macular Degeneration (AMD) treatment Beovu (brolucizumab) has passed the first threshold to win the healthcare reimbursement in South Korea. The pharmaceutical industry sources reported the Health Insurance Review and Assessment Service (HIRA) Drug Reimbursement Evaluation Committee (DREC) recently green l
